Novel ITP Drug Helps Patients Ditch Daily Meds

(MedPage Today) — ORLANDO — Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily treatment with an oral platelet…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118904

Author :

Publish date : 2025-12-09 15:09:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Novel ITP Drug Helps Patients Ditch Daily Meds

FDA Probes RSV Drug Safety; Why Some Cancers Shouldn’t Be Treated; New Mpox Strain

New BTK Inhibitor Makes Case for Earlier Use in CLL

Related Posts

New BTK Inhibitor Makes Case for Earlier Use in CLL

FDA Probes RSV Drug Safety; Why Some Cancers Shouldn’t Be Treated; New Mpox Strain

GLP-1s and Cancer: Meta-analysis Shows Little or No Link

Reducing Hospital Readmissions From Nursing Facilities

IL-6 Vaccine Shows Early Benefit in Knee Osteoarthritis

Helping Patients Transition From Pediatrics to Your Practice

New BTK Inhibitor Makes Case for Earlier Use in CLL

Novel ITP Drug Helps Patients Ditch Daily Meds

FDA Probes RSV Drug Safety; Why Some Cancers Shouldn’t Be Treated; New Mpox Strain

GLP-1s and Cancer: Meta-analysis Shows Little or No Link

Reducing Hospital Readmissions From Nursing Facilities

IL-6 Vaccine Shows Early Benefit in Knee Osteoarthritis

Helping Patients Transition From Pediatrics to Your Practice

Lower Risk Groups Can Cut Back on Cervical Cancer Screening

Categories

Archives